Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned a consensus recommendation of "Buy" from the nine analysts that are currently covering the stock, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $57.38.
XENE has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Royal Bank of Canada reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price objective for the company.
Get Our Latest Research Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Down 6.1 %
Shares of Xenon Pharmaceuticals stock traded down $2.23 during trading hours on Friday, reaching $34.27. 408,442 shares of the company's stock were exchanged, compared to its average volume of 376,650. The business has a fifty day moving average of $39.06 and a two-hundred day moving average of $40.24. The company has a market capitalization of $2.62 billion, a P/E ratio of -12.15 and a beta of 1.26. Xenon Pharmaceuticals has a 1 year low of $33.27 and a 1 year high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.05. As a group, research analysts predict that Xenon Pharmaceuticals will post -3.1 EPS for the current year.
Insider Buying and Selling
In other news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the business's stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Insiders sold 57,492 shares of company stock valued at $2,334,969 in the last three months. 5.52% of the stock is owned by corporate insiders.
Institutional Trading of Xenon Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in Xenon Pharmaceuticals during the fourth quarter worth approximately $63,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Xenon Pharmaceuticals by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 191,852 shares of the biopharmaceutical company's stock worth $7,521,000 after purchasing an additional 29,169 shares in the last quarter. Woodline Partners LP purchased a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $1,566,000. Vident Advisory LLC acquired a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at $212,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of Xenon Pharmaceuticals by 9.1% in the 4th quarter. Two Sigma Advisers LP now owns 298,700 shares of the biopharmaceutical company's stock valued at $11,709,000 after buying an additional 25,000 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.
About Xenon Pharmaceuticals
(
Get Free ReportXenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
